Q&A: Brent Saunders on pushing Bausch out of neutral, scrutinizing new hires and why TrumpRx matters

Brent speaks with Senior Biopharma Correspondent Andrew Dunn for an Endpoints News feature nearly three years after his return to Bausch + Lomb.